Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.50 |
| ▸ | AKT1S1 | Q96B36 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 6/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669763 | 0.98 | RPS6KB1 (0.49) | RPS6KB1AKT1S1TP53P2RX7LMNA | |
| SCHEMBL16461381 | 0.96 | RPS6KB1 (0.50) | RPS6KB1AKT1S1TP53P2RX7LMNA | |
| SCHEMBL16461842 | 0.86 | DPP4 (0.55) | RPS6KB1AKT1S1TP53P2RX7LMNA | |
| SCHEMBL15719175 | 0.84 | CYP2D6 (0.62) | RPS6KB1AKT1S1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26921276 | 0.84 | CHRM2 (0.55) | RPS6KB1AKT1S1LMNAKMT2ACYP3A4 | |
| SCHEMBL18824466 | 0.84 | DPP4 (0.60) | RPS6KB1AKT1S1TP53P2RX7LMNA | |
| SCHEMBL4731651 | 0.84 | TP53 (0.47) | TP53P2RX7LMNATHRBCYP1A2 | |
| SCHEMBL8276868 | 0.84 | DPP4 (0.60) | RPS6KB1AKT1S1TP53P2RX7LMNA | |
| Hydrochloric Acid SCHEMBL17107338 | 0.83 | CYP2D6 (0.60) | RPS6KB1AKT1S1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16460945 | 0.82 | P2RX7 (0.51) | RPS6KB1AKT1S1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307766-A1 | CYCLIC AMINES | MINDIMMUNE THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190307766-A1 | CYCLIC AMINES | MINDIMMUNE THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3536689-A1 | 2-(CYCLIC AMINEETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MindImmune Therapeutics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3536689-A1 | 2-(CYCLIC AMINEETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MindImmune Therapeutics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2906549-B1 | N-(2-(CYCLIC AMINE)ETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MINDIMMUNE THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2906549-B1 | N-(2-(CYCLIC AMINE)ETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS | MINDIMMUNE THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10124010-B2 | Cyclic amines | MINDIMMUNE THERAPEUTICS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180177793-A1 | CYCLIC AMINES | MINDIMMUNE THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-9861639-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2018-01-09 | — | — | US | disclosed |
| US-9861639-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2018-01-09 | — | — | US | disclosed |
| CN-104955819-A | N-(2-(cyclic amine)ethyl)benzamide derivatives as P2X7 inhibitors | LUNDBECK & CO AS H | 2015-09-30 | — | — | CN | disclosed |
| EP-2906549-A2 | CYCLIC AMINES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9108938-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2015-08-18 | — | — | US | disclosed |
| US-9108938-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2015-08-18 | — | — | US | disclosed |
| US-9108938-B2 | Cyclic amines | H. LUNDBECK A/S (DK) | 2015-08-18 | — | — | US | disclosed |
| US-20140107335-A1 | Cyclic Amines | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| US-20140107335-A1 | Cyclic Amines | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057080-A2 | CYCLIC AMINES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| US-20140107335-A1 | Cyclic Amines | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057080-A2 | CYCLIC AMINES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307766-A1 | CYCLIC AMINES | P2RX7, ADORA2A, P2RX2 | RPS6KB1 2290/4885AKT1S1 2617/4885TP53 4835/4885 |
| US-20140107335-A1 | Cyclic Amines | P2RX7, ADORA2A, P2RX2 | RPS6KB1 2290/4885AKT1S1 2617/4885TP53 4835/4885 |
| US-10124010-B2 | Cyclic amines | P2RX7, ADORA2A, P2RX2 | RPS6KB1 2290/4885AKT1S1 2617/4885TP53 4835/4885 |
| US-20180177793-A1 | CYCLIC AMINES | P2RX7, ADORA2A, P2RX2 | RPS6KB1 2290/4885AKT1S1 2617/4885TP53 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.